MVP方案动脉灌注治疗非小细胞肺癌临床探究.docVIP

MVP方案动脉灌注治疗非小细胞肺癌临床探究[摘要] 目的 观察MVP方案动脉灌注治疗非小细胞肺癌（NSCLC）的临床疗效。 方法 选择2007年1月～2010年12月收治的经病理证实的NSCLC患者100例采用MVP方案[丝裂霉素（MMC）+长春地辛（VDS）+顺铂（DDP）]、支气管动脉灌注（BAI）治疗，BAI治疗每例至少2次。 结果 本组总有效率84％，总体生存期13个月，中位生存期平均16个月，一年生存率78％。多数患者治疗后疼痛减轻、肿块缩小、通气改善、血痰消失或减少、肺不张复张。多、中血供型肺癌明显高于少血供型肺癌（P ＜ 0.01）。结论 MVP方案、BAI治疗NSCLC效果确切，值得临床推广应用。 [关键词] 化疗；动脉灌注；非小细胞肺癌；介入 [中图分类号] R734.2 [文献标识码] B [文章编号] 1673-9701（2012）03-0148-02 The clinical research of MVP scheme artery perfusion in treatment of non-small-cell lung cancer CAO Qiang1 RONG Yang2 1.Department of Radiology and Intervention, the Third Hospital of Liaoyang in Liaoning Province, Liaoyang 111000, China; 2.Department of Radiology, Liaoyang Center Hospital Affiliated China Medical University, Liaoyang 111000, China [Abstract] Objective To observe the effect of MVP scheme artery perfusion treatment on the non-small-cell lung cancer (NSCLC) curative. Methods All of 100 patients with NSCLC pathologically proved from Jan 2007 to Nov 2010 were given MVP [Mitomycin (MMC) + Vindesine (VDS) + Cisplatin (DDP)] and the bronchial arterial perfusion (BAI)(each patient at least twice). Results The total effective rate was 84%, total survival time was 13 months, median survival time was 16 months, and one-year survival rate was 78%. Most patients pain mitigated, mass narrowed, improve ventilation, blood sputum disappear or reduce, ventilation improved significantly. In the more blood supply for lung cancer was significantly higher than the less blood supply for lung cancer (P ＜ 0.01). Conclusion MVP plan BAI has a good result in the treatment of NSCLC. [Key words] Chemotherapy; Artery perfusion; Non-small cell lung cancer; Iintervention 介入治疗是目前治疗中晚期肺癌的有效方法之一，2007年1月～2010年12月用MVP方案、BAI治疗非小细胞肺癌（NSCLC）100例，疗效满意，现报道如下。 1 资料与方法 1.1 一般资料 本组病例均经病理证实，其中男性72例，女性28例；年龄42～74岁，平均57.6岁；中心型56例，周围型44例；组织类型：鳞癌58例、腺癌42例；参照国际抗癌联盟（UICC）的分期标准[1]：Ⅱ期18例，Ⅲa期66例，Ⅳ期16例。病史3～9个月，平均4.4个月；主要症状：咳嗽、气短、胸痛、痰中带血、消瘦；治疗前生活质量Kamofsky评分法评定≥80分40例，70分34例，60分26例。 1